

Global GLP-1 Combination and Multi-agonist Drugs Market Growth 2026-2032

<https://marketpublishers.com/r/GDBA2CECA37EEN.html>

Date: July 2026

Pages: 105

Price: US\$ 3,660.00 (Single User License)

ID: GDBA2CECA37EEN

Abstracts

The global GLP-1 Combination and Multi-agonist Drugs market size is predicted to grow from US\$ 18338 million in 2025 to US\$ 61932 million in 2032; it is expected to grow at a CAGR of 18.2% from 2026 to 2032.

GLP-1 combination and multi-agonist drugs are innovative medicines built around the GLP-1 pathway while also engaging GIP, glucagon, amylin or other metabolic targets to improve body weight, glucose control, fatty liver disease and cardiometabolic risk through synergistic mechanisms. The category includes dual agonists, tri-agonists, fixed-dose combinations and combination candidates, with evaluation focused on greater weight reduction, broader metabolic benefit, safety, dosing convenience and long-term adherence. In 2025, global GLP-1 Combination and Multi-agonist Drugs production reached approximately 320 million unit. The average gross profit margin of this product is 80%.

GLP-1 combination and multi-agonist drugs are among the most active innovation areas in obesity and metabolic disease. Dual- and tri-target mechanisms may further improve weight-loss efficacy beyond traditional GLP-1 therapy and expand use into diabetes, MASH and broader cardiometabolic risk management.

Industrial competition is concentrated among large global pharmaceutical companies and selected innovative biotechnology firms. Approved dual agonists have accelerated market education and physician adoption, while late-stage tri-agonists, GLP-1/glucagon dual agonists and amylin combinations may drive the next wave of differentiation.

Growth is influenced by clinical trial outcomes, long-term safety, capacity scale-up, drug pricing and payer coverage. Future market focus will shift toward the upper limit of

efficacy, muscle-mass preservation, post-treatment weight management, liver metabolic improvement and integrated chronic disease care.

LP Information, Inc. (LPI) ' newest research report, the "GLP-1 Combination and Multi-agonist Drugs Industry Forecast" looks at past sales and reviews total world GLP-1 Combination and Multi-agonist Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected GLP-1 Combination and Multi-agonist Drugs sales for 2026 through 2032. With GLP-1 Combination and Multi-agonist Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world GLP-1 Combination and Multi-agonist Drugs industry.

This Insight Report provides a comprehensive analysis of the global GLP-1 Combination and Multi-agonist Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on GLP-1 Combination and Multi-agonist Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global GLP-1 Combination and Multi-agonist Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GLP-1 Combination and Multi-agonist Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GLP-1 Combination and Multi-agonist Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of GLP-1 Combination and Multi-agonist Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

GIP/GLP-1 Dual Agonist

GLP-1/Glucagon Dual Agonist

Amylin/GLP-1 Combination

GIP/GLP-1/Glucagon Tri-agonist

GLP-1 Plus Small Molecule

Other

Segmentation by Indication:

Obesity

Type 2 Diabetes

MASH

Cardiometabolic Disease

Other

Segmentation by Dosage Form:

Peptide Injection

Long-acting Injection

Oral Candidate

Combination Kit

Other

Segmentation by Application:

Obesity Clinics

Endocrinology Departments

Metabolic Disease Centers

Clinical Trial Sites

Hospital Pharmacies

Retail Pharmacies

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Eli Lilly

Novo Nordisk

Boehringer Ingelheim

AstraZeneca

Sanofi

GSK

Hansoh

Huiren Bio

Key Questions Addressed in this Report

What is the 10-year outlook for the global GLP-1 Combination and Multi-agonist Drugs market?

What factors are driving GLP-1 Combination and Multi-agonist Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do GLP-1 Combination and Multi-agonist Drugs market opportunities vary by end market size?

How does GLP-1 Combination and Multi-agonist Drugs break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global GLP-1 Combination and Multi-agonist Drugs Annual Sales 2021-2032
- 2.1.2 World Current & Future Analysis for GLP-1 Combination and Multi-agonist Drugs by Geographic Region, 2021, 2025 & 2032
- 2.1.3 World Current & Future Analysis for GLP-1 Combination and Multi-agonist Drugs by Country/Region, 2021, 2025 & 2032

2.2 GLP-1 Combination and Multi-agonist Drugs Segment by Type

- 2.2.1 GIP/GLP-1 Dual Agonist
- 2.2.2 GLP-1/Glucagon Dual Agonist
- 2.2.3 Amylin/GLP-1 Combination
- 2.2.4 GIP/GLP-1/Glucagon Tri-agonist
- 2.2.5 GLP-1 Plus Small Molecule
- 2.2.6 Other
- 2.2.7 GLP-1 Combination and Multi-agonist Drugs Sales by Type
 - 2.2.7.1 Global GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Type (2021-2026)
 - 2.2.7.2 Global GLP-1 Combination and Multi-agonist Drugs Revenue and Market Share by Type (2021-2026)
 - 2.2.7.3 Global GLP-1 Combination and Multi-agonist Drugs Sale Price by Type (2021-2026)

2.3 GLP-1 Combination and Multi-agonist Drugs Segment by Indication

- 2.3.1 Obesity
- 2.3.2 Type 2 Diabetes
- 2.3.3 MASH

2.3.4 Cardiometabolic Disease

2.3.5 Other

2.3.6 GLP-1 Combination and Multi-agonist Drugs Sales by Indication

2.3.6.1 Global GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Indication (2021-2026)

2.3.6.2 Global GLP-1 Combination and Multi-agonist Drugs Revenue and Market Share by Indication (2021-2026)

2.3.6.3 Global GLP-1 Combination and Multi-agonist Drugs Sale Price by Indication (2021-2026)

2.4 GLP-1 Combination and Multi-agonist Drugs Segment by Dosage Form

2.4.1 Peptide Injection

2.4.2 Long-acting Injection

2.4.3 Oral Candidate

2.4.4 Combination Kit

2.4.5 Other

2.4.6 GLP-1 Combination and Multi-agonist Drugs Sales by Dosage Form

2.4.6.1 Global GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Dosage Form (2021-2026)

2.4.6.2 Global GLP-1 Combination and Multi-agonist Drugs Revenue and Market Share by Dosage Form (2021-2026)

2.4.6.3 Global GLP-1 Combination and Multi-agonist Drugs Sale Price by Dosage Form (2021-2026)

2.5 GLP-1 Combination and Multi-agonist Drugs Segment by Application

2.5.1 Obesity Clinics

2.5.2 Endocrinology Departments

2.5.3 Metabolic Disease Centers

2.5.4 Clinical Trial Sites

2.5.5 Hospital Pharmacies

2.5.6 Retail Pharmacies

2.5.7 Other

2.5.8 GLP-1 Combination and Multi-agonist Drugs Sales by Application

2.5.8.1 Global GLP-1 Combination and Multi-agonist Drugs Sale Market Share by Application (2021-2026)

2.5.8.2 Global GLP-1 Combination and Multi-agonist Drugs Revenue and Market Share by Application (2021-2026)

2.5.8.3 Global GLP-1 Combination and Multi-agonist Drugs Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global GLP-1 Combination and Multi-agonist Drugs Breakdown Data by Company

3.1.1 Global GLP-1 Combination and Multi-agonist Drugs Annual Sales by Company (2021-2026)

3.1.2 Global GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Company (2021-2026)

3.2 Global GLP-1 Combination and Multi-agonist Drugs Annual Revenue by Company (2021-2026)

3.2.1 Global GLP-1 Combination and Multi-agonist Drugs Revenue by Company (2021-2026)

3.2.2 Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Company (2021-2026)

3.3 Global GLP-1 Combination and Multi-agonist Drugs Sale Price by Company

3.4 Key Manufacturers GLP-1 Combination and Multi-agonist Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers GLP-1 Combination and Multi-agonist Drugs Product Location Distribution

3.4.2 Players GLP-1 Combination and Multi-agonist Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR GLP-1 COMBINATION AND MULTI-AGONIST DRUGS BY GEOGRAPHIC REGION

4.1 World Historic GLP-1 Combination and Multi-agonist Drugs Market Size by Geographic Region (2021-2026)

4.1.1 Global GLP-1 Combination and Multi-agonist Drugs Annual Sales by Geographic Region (2021-2026)

4.1.2 Global GLP-1 Combination and Multi-agonist Drugs Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic GLP-1 Combination and Multi-agonist Drugs Market Size by Country/Region (2021-2026)

4.2.1 Global GLP-1 Combination and Multi-agonist Drugs Annual Sales by Country/Region (2021-2026)

4.2.2 Global GLP-1 Combination and Multi-agonist Drugs Annual Revenue by Country/Region (2021-2026)

- 4.3 Americas GLP-1 Combination and Multi-agonist Drugs Sales Growth
- 4.4 APAC GLP-1 Combination and Multi-agonist Drugs Sales Growth
- 4.5 Europe GLP-1 Combination and Multi-agonist Drugs Sales Growth
- 4.6 Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales Growth

5 AMERICAS

- 5.1 Americas GLP-1 Combination and Multi-agonist Drugs Sales by Country
 - 5.1.1 Americas GLP-1 Combination and Multi-agonist Drugs Sales by Country (2021-2026)
 - 5.1.2 Americas GLP-1 Combination and Multi-agonist Drugs Revenue by Country (2021-2026)
- 5.2 Americas GLP-1 Combination and Multi-agonist Drugs Sales by Type (2021-2026)
- 5.3 Americas GLP-1 Combination and Multi-agonist Drugs Sales by Application (2021-2026)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC GLP-1 Combination and Multi-agonist Drugs Sales by Region
 - 6.1.1 APAC GLP-1 Combination and Multi-agonist Drugs Sales by Region (2021-2026)
 - 6.1.2 APAC GLP-1 Combination and Multi-agonist Drugs Revenue by Region (2021-2026)
- 6.2 APAC GLP-1 Combination and Multi-agonist Drugs Sales by Type (2021-2026)
- 6.3 APAC GLP-1 Combination and Multi-agonist Drugs Sales by Application (2021-2026)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

7.1 Europe GLP-1 Combination and Multi-agonist Drugs by Country

7.1.1 Europe GLP-1 Combination and Multi-agonist Drugs Sales by Country (2021-2026)

7.1.2 Europe GLP-1 Combination and Multi-agonist Drugs Revenue by Country (2021-2026)

7.2 Europe GLP-1 Combination and Multi-agonist Drugs Sales by Type (2021-2026)

7.3 Europe GLP-1 Combination and Multi-agonist Drugs Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa GLP-1 Combination and Multi-agonist Drugs by Country

8.1.1 Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales by Country (2021-2026)

8.1.2 Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Revenue by Country (2021-2026)

8.2 Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales by Type (2021-2026)

8.3 Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of GLP-1 Combination and Multi-agonist Drugs

10.3 Manufacturing Process Analysis of GLP-1 Combination and Multi-agonist Drugs

10.4 Industry Chain Structure of GLP-1 Combination and Multi-agonist Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 GLP-1 Combination and Multi-agonist Drugs Distributors

11.3 GLP-1 Combination and Multi-agonist Drugs Customer

12 WORLD FORECAST REVIEW FOR GLP-1 COMBINATION AND MULTI-AGONIST DRUGS BY GEOGRAPHIC REGION

12.1 Global GLP-1 Combination and Multi-agonist Drugs Market Size Forecast by Region

12.1.1 Global GLP-1 Combination and Multi-agonist Drugs Forecast by Region (2027-2032)

12.1.2 Global GLP-1 Combination and Multi-agonist Drugs Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global GLP-1 Combination and Multi-agonist Drugs Forecast by Type (2027-2032)

12.7 Global GLP-1 Combination and Multi-agonist Drugs Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Eli Lilly

13.1.1 Eli Lilly Company Information

13.1.2 Eli Lilly GLP-1 Combination and Multi-agonist Drugs Product Portfolios and Specifications

13.1.3 Eli Lilly GLP-1 Combination and Multi-agonist Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

- 13.1.4 Eli Lilly Main Business Overview
- 13.1.5 Eli Lilly Latest Developments
- 13.2 Novo Nordisk
 - 13.2.1 Novo Nordisk Company Information
 - 13.2.2 Novo Nordisk GLP-1 Combination and Multi-agonist Drugs Product Portfolios and Specifications
 - 13.2.3 Novo Nordisk GLP-1 Combination and Multi-agonist Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.2.4 Novo Nordisk Main Business Overview
 - 13.2.5 Novo Nordisk Latest Developments
- 13.3 Boehringer Ingelheim
 - 13.3.1 Boehringer Ingelheim Company Information
 - 13.3.2 Boehringer Ingelheim GLP-1 Combination and Multi-agonist Drugs Product Portfolios and Specifications
 - 13.3.3 Boehringer Ingelheim GLP-1 Combination and Multi-agonist Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.3.4 Boehringer Ingelheim Main Business Overview
 - 13.3.5 Boehringer Ingelheim Latest Developments
- 13.4 AstraZeneca
 - 13.4.1 AstraZeneca Company Information
 - 13.4.2 AstraZeneca GLP-1 Combination and Multi-agonist Drugs Product Portfolios and Specifications
 - 13.4.3 AstraZeneca GLP-1 Combination and Multi-agonist Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.4.4 AstraZeneca Main Business Overview
 - 13.4.5 AstraZeneca Latest Developments
- 13.5 Sanofi
 - 13.5.1 Sanofi Company Information
 - 13.5.2 Sanofi GLP-1 Combination and Multi-agonist Drugs Product Portfolios and Specifications
 - 13.5.3 Sanofi GLP-1 Combination and Multi-agonist Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.5.4 Sanofi Main Business Overview
 - 13.5.5 Sanofi Latest Developments
- 13.6 GSK
 - 13.6.1 GSK Company Information
 - 13.6.2 GSK GLP-1 Combination and Multi-agonist Drugs Product Portfolios and Specifications
 - 13.6.3 GSK GLP-1 Combination and Multi-agonist Drugs Sales, Revenue, Price and

Gross Margin (2021-2026)

13.6.4 GSK Main Business Overview

13.6.5 GSK Latest Developments

13.7 Hansoh

13.7.1 Hansoh Company Information

13.7.2 Hansoh GLP-1 Combination and Multi-agonist Drugs Product Portfolios and Specifications

13.7.3 Hansoh GLP-1 Combination and Multi-agonist Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 Hansoh Main Business Overview

13.7.5 Hansoh Latest Developments

13.8 Huiren Bio

13.8.1 Huiren Bio Company Information

13.8.2 Huiren Bio GLP-1 Combination and Multi-agonist Drugs Product Portfolios and Specifications

13.8.3 Huiren Bio GLP-1 Combination and Multi-agonist Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Huiren Bio Main Business Overview

13.8.5 Huiren Bio Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. GLP-1 Combination and Multi-agonist Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Table 2. GLP-1 Combination and Multi-agonist Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)
- Table 3. Major Players of GIP/GLP-1 Dual Agonist
- Table 4. Major Players of GLP-1/Glucagon Dual Agonist
- Table 5. Major Players of Amylin/GLP-1 Combination
- Table 6. Major Players of GIP/GLP-1/Glucagon Tri-agonist
- Table 7. Major Players of GLP-1 Plus Small Molecule
- Table 8. Major Players of Other
- Table 9. Global GLP-1 Combination and Multi-agonist Drugs Sales by Type (2021-2026) & (K Units)
- Table 10. Global GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Type (2021-2026)
- Table 11. Global GLP-1 Combination and Multi-agonist Drugs Revenue by Type (2021-2026) & (\$ million)
- Table 12. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Type (2021-2026)
- Table 13. Global GLP-1 Combination and Multi-agonist Drugs Sale Price by Type (2021-2026) & (US\$/Unit)
- Table 14. Major Players of Obesity
- Table 15. Major Players of Type 2 Diabetes
- Table 16. Major Players of MASH
- Table 17. Major Players of Cardiometabolic Disease
- Table 18. Major Players of Other
- Table 19. Global GLP-1 Combination and Multi-agonist Drugs Sales by Indication (2021-2026) & (K Units)
- Table 20. Global GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Indication (2021-2026)
- Table 21. Global GLP-1 Combination and Multi-agonist Drugs Revenue by Indication (2021-2026) & (\$ million)
- Table 22. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Indication (2021-2026)
- Table 23. Global GLP-1 Combination and Multi-agonist Drugs Sale Price by Indication (2021-2026) & (US\$/Unit)

Table 24. Major Players of Peptide Injection

Table 25. Major Players of Long-acting Injection

Table 26. Major Players of Oral Candidate

Table 27. Major Players of Combination Kit

Table 28. Major Players of Other

Table 29. Global GLP-1 Combination and Multi-agonist Drugs Sales by Dosage Form (2021-2026) & (K Units)

Table 30. Global GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Dosage Form (2021-2026)

Table 31. Global GLP-1 Combination and Multi-agonist Drugs Revenue by Dosage Form (2021-2026) & (\$ million)

Table 32. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Dosage Form (2021-2026)

Table 33. Global GLP-1 Combination and Multi-agonist Drugs Sale Price by Dosage Form (2021-2026) & (US\$/Unit)

Table 34. Global GLP-1 Combination and Multi-agonist Drugs Sale by Application (2021-2026) & (K Units)

Table 35. Global GLP-1 Combination and Multi-agonist Drugs Sale Market Share by Application (2021-2026)

Table 36. Global GLP-1 Combination and Multi-agonist Drugs Revenue by Application (2021-2026) & (\$ million)

Table 37. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Application (2021-2026)

Table 38. Global GLP-1 Combination and Multi-agonist Drugs Sale Price by Application (2021-2026) & (US\$/Unit)

Table 39. Global GLP-1 Combination and Multi-agonist Drugs Sales by Company (2021-2026) & (K Units)

Table 40. Global GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Company (2021-2026)

Table 41. Global GLP-1 Combination and Multi-agonist Drugs Revenue by Company (2021-2026) & (\$ millions)

Table 42. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Company (2021-2026)

Table 43. Global GLP-1 Combination and Multi-agonist Drugs Sale Price by Company (2021-2026) & (US\$/Unit)

Table 44. Key Manufacturers GLP-1 Combination and Multi-agonist Drugs Producing Area Distribution and Sales Area

Table 45. Players GLP-1 Combination and Multi-agonist Drugs Products Offered

Table 46. GLP-1 Combination and Multi-agonist Drugs Concentration Ratio (CR3, CR5)

and CR10) & (2024-2026)

Table 47. New Products and Potential Entrants

Table 48. Market M&A Activity & Strategy

Table 49. Global GLP-1 Combination and Multi-agonist Drugs Sales by Geographic Region (2021-2026) & (K Units)

Table 50. Global GLP-1 Combination and Multi-agonist Drugs Sales Market Share Geographic Region (2021-2026)

Table 51. Global GLP-1 Combination and Multi-agonist Drugs Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 52. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Geographic Region (2021-2026)

Table 53. Global GLP-1 Combination and Multi-agonist Drugs Sales by Country/Region (2021-2026) & (K Units)

Table 54. Global GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Country/Region (2021-2026)

Table 55. Global GLP-1 Combination and Multi-agonist Drugs Revenue by Country/Region (2021-2026) & (\$ millions)

Table 56. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Country/Region (2021-2026)

Table 57. Americas GLP-1 Combination and Multi-agonist Drugs Sales by Country (2021-2026) & (K Units)

Table 58. Americas GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Country (2021-2026)

Table 59. Americas GLP-1 Combination and Multi-agonist Drugs Revenue by Country (2021-2026) & (\$ millions)

Table 60. Americas GLP-1 Combination and Multi-agonist Drugs Sales by Type (2021-2026) & (K Units)

Table 61. Americas GLP-1 Combination and Multi-agonist Drugs Sales by Application (2021-2026) & (K Units)

Table 62. APAC GLP-1 Combination and Multi-agonist Drugs Sales by Region (2021-2026) & (K Units)

Table 63. APAC GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Region (2021-2026)

Table 64. APAC GLP-1 Combination and Multi-agonist Drugs Revenue by Region (2021-2026) & (\$ millions)

Table 65. APAC GLP-1 Combination and Multi-agonist Drugs Sales by Type (2021-2026) & (K Units)

Table 66. APAC GLP-1 Combination and Multi-agonist Drugs Sales by Application (2021-2026) & (K Units)

Table 67. Europe GLP-1 Combination and Multi-agonist Drugs Sales by Country (2021-2026) & (K Units)
Table 68. Europe GLP-1 Combination and Multi-agonist Drugs Revenue by Country (2021-2026) & (\$ millions)
Table 69. Europe GLP-1 Combination and Multi-agonist Drugs Sales by Type (2021-2026) & (K Units)
Table 70. Europe GLP-1 Combination and Multi-agonist Drugs Sales by Application (2021-2026) & (K Units)
Table 71. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales by Country (2021-2026) & (K Units)
Table 72. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Country (2021-2026)
Table 73. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales by Type (2021-2026) & (K Units)
Table 74. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales by Application (2021-2026) & (K Units)
Table 75. Key Market Drivers & Growth Opportunities of GLP-1 Combination and Multi-agonist Drugs
Table 76. Key Market Challenges & Risks of GLP-1 Combination and Multi-agonist Drugs
Table 77. Key Industry Trends of GLP-1 Combination and Multi-agonist Drugs
Table 78. GLP-1 Combination and Multi-agonist Drugs Raw Material
Table 79. Key Suppliers of Raw Materials
Table 80. GLP-1 Combination and Multi-agonist Drugs Distributors List
Table 81. GLP-1 Combination and Multi-agonist Drugs Customer List
Table 82. Global GLP-1 Combination and Multi-agonist Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 83. Global GLP-1 Combination and Multi-agonist Drugs Revenue Forecast by Region (2027-2032) & (\$ millions)
Table 84. Americas GLP-1 Combination and Multi-agonist Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 85. Americas GLP-1 Combination and Multi-agonist Drugs Annual Revenue Forecast by Country (2027-2032) & (\$ millions)
Table 86. APAC GLP-1 Combination and Multi-agonist Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 87. APAC GLP-1 Combination and Multi-agonist Drugs Annual Revenue Forecast by Region (2027-2032) & (\$ millions)
Table 88. Europe GLP-1 Combination and Multi-agonist Drugs Sales Forecast by Country (2027-2032) & (K Units)

Table 89. Europe GLP-1 Combination and Multi-agonist Drugs Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 90. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales Forecast by Country (2027-2032) & (K Units)

Table 91. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 92. Global GLP-1 Combination and Multi-agonist Drugs Sales Forecast by Type (2027-2032) & (K Units)

Table 93. Global GLP-1 Combination and Multi-agonist Drugs Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 94. Global GLP-1 Combination and Multi-agonist Drugs Sales Forecast by Application (2027-2032) & (K Units)

Table 95. Global GLP-1 Combination and Multi-agonist Drugs Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 96. Eli Lilly Basic Information, GLP-1 Combination and Multi-agonist Drugs Manufacturing Base, Sales Area and Its Competitors

Table 97. Eli Lilly GLP-1 Combination and Multi-agonist Drugs Product Portfolios and Specifications

Table 98. Eli Lilly GLP-1 Combination and Multi-agonist Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 99. Eli Lilly Main Business

Table 100. Eli Lilly Latest Developments

Table 101. Novo Nordisk Basic Information, GLP-1 Combination and Multi-agonist Drugs Manufacturing Base, Sales Area and Its Competitors

Table 102. Novo Nordisk GLP-1 Combination and Multi-agonist Drugs Product Portfolios and Specifications

Table 103. Novo Nordisk GLP-1 Combination and Multi-agonist Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 104. Novo Nordisk Main Business

Table 105. Novo Nordisk Latest Developments

Table 106. Boehringer Ingelheim Basic Information, GLP-1 Combination and Multi-agonist Drugs Manufacturing Base, Sales Area and Its Competitors

Table 107. Boehringer Ingelheim GLP-1 Combination and Multi-agonist Drugs Product Portfolios and Specifications

Table 108. Boehringer Ingelheim GLP-1 Combination and Multi-agonist Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 109. Boehringer Ingelheim Main Business

Table 110. Boehringer Ingelheim Latest Developments

Table 111. AstraZeneca Basic Information, GLP-1 Combination and Multi-agonist Drugs

Manufacturing Base, Sales Area and Its Competitors

Table 112. AstraZeneca GLP-1 Combination and Multi-agonist Drugs Product Portfolios and Specifications

Table 113. AstraZeneca GLP-1 Combination and Multi-agonist Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 114. AstraZeneca Main Business

Table 115. AstraZeneca Latest Developments

Table 116. Sanofi Basic Information, GLP-1 Combination and Multi-agonist Drugs Manufacturing Base, Sales Area and Its Competitors

Table 117. Sanofi GLP-1 Combination and Multi-agonist Drugs Product Portfolios and Specifications

Table 118. Sanofi GLP-1 Combination and Multi-agonist Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 119. Sanofi Main Business

Table 120. Sanofi Latest Developments

Table 121. GSK Basic Information, GLP-1 Combination and Multi-agonist Drugs Manufacturing Base, Sales Area and Its Competitors

Table 122. GSK GLP-1 Combination and Multi-agonist Drugs Product Portfolios and Specifications

Table 123. GSK GLP-1 Combination and Multi-agonist Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 124. GSK Main Business

Table 125. GSK Latest Developments

Table 126. Hansoh Basic Information, GLP-1 Combination and Multi-agonist Drugs Manufacturing Base, Sales Area and Its Competitors

Table 127. Hansoh GLP-1 Combination and Multi-agonist Drugs Product Portfolios and Specifications

Table 128. Hansoh GLP-1 Combination and Multi-agonist Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 129. Hansoh Main Business

Table 130. Hansoh Latest Developments

Table 131. Huiren Bio Basic Information, GLP-1 Combination and Multi-agonist Drugs Manufacturing Base, Sales Area and Its Competitors

Table 132. Huiren Bio GLP-1 Combination and Multi-agonist Drugs Product Portfolios and Specifications

Table 133. Huiren Bio GLP-1 Combination and Multi-agonist Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 134. Huiren Bio Main Business

Table 135. Huiren Bio Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of GLP-1 Combination and Multi-agonist Drugs
- Figure 2. GLP-1 Combination and Multi-agonist Drugs Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global GLP-1 Combination and Multi-agonist Drugs Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global GLP-1 Combination and Multi-agonist Drugs Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. GLP-1 Combination and Multi-agonist Drugs Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Country/Region (2025)
- Figure 10. GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of GIP/GLP-1 Dual Agonist
- Figure 12. Product Picture of GLP-1/Glucagon Dual Agonist
- Figure 13. Product Picture of Amylin/GLP-1 Combination
- Figure 14. Product Picture of GIP/GLP-1/Glucagon Tri-agonist
- Figure 15. Product Picture of GLP-1 Plus Small Molecule
- Figure 16. Product Picture of Other
- Figure 17. Global GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Type in 2026
- Figure 18. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Type (2021-2026)
- Figure 19. Product Picture of Obesity
- Figure 20. Product Picture of Type 2 Diabetes
- Figure 21. Product Picture of MASH
- Figure 22. Product Picture of Cardiometabolic Disease
- Figure 23. Product Picture of Other
- Figure 24. Global GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Indication in 2026
- Figure 25. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Indication (2021-2026)
- Figure 26. Product Picture of Peptide Injection

Figure 27. Product Picture of Long-acting Injection

Figure 28. Product Picture of Oral Candidate

Figure 29. Product Picture of Combination Kit

Figure 30. Product Picture of Other

Figure 31. Global GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Dosage Form in 2026

Figure 32. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Dosage Form (2021-2026)

Figure 33. GLP-1 Combination and Multi-agonist Drugs Consumed in Obesity Clinics

Figure 34. Global GLP-1 Combination and Multi-agonist Drugs Market: Obesity Clinics (2021-2026) & (K Units)

Figure 35. GLP-1 Combination and Multi-agonist Drugs Consumed in Endocrinology Departments

Figure 36. Global GLP-1 Combination and Multi-agonist Drugs Market: Endocrinology Departments (2021-2026) & (K Units)

Figure 37. GLP-1 Combination and Multi-agonist Drugs Consumed in Metabolic Disease Centers

Figure 38. Global GLP-1 Combination and Multi-agonist Drugs Market: Metabolic Disease Centers (2021-2026) & (K Units)

Figure 39. GLP-1 Combination and Multi-agonist Drugs Consumed in Clinical Trial Sites

Figure 40. Global GLP-1 Combination and Multi-agonist Drugs Market: Clinical Trial Sites (2021-2026) & (K Units)

Figure 41. GLP-1 Combination and Multi-agonist Drugs Consumed in Hospital Pharmacies

Figure 42. Global GLP-1 Combination and Multi-agonist Drugs Market: Hospital Pharmacies (2021-2026) & (K Units)

Figure 43. GLP-1 Combination and Multi-agonist Drugs Consumed in Retail Pharmacies

Figure 44. Global GLP-1 Combination and Multi-agonist Drugs Market: Retail Pharmacies (2021-2026) & (K Units)

Figure 45. GLP-1 Combination and Multi-agonist Drugs Consumed in Other

Figure 46. Global GLP-1 Combination and Multi-agonist Drugs Market: Other (2021-2026) & (K Units)

Figure 47. Global GLP-1 Combination and Multi-agonist Drugs Sale Market Share by Application (2025)

Figure 48. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Application in 2025

Figure 49. GLP-1 Combination and Multi-agonist Drugs Sales by Company in 2025 (K Units)

Figure 50. Global GLP-1 Combination and Multi-agonist Drugs Sales Market Share by

Company in 2025

Figure 51. GLP-1 Combination and Multi-agonist Drugs Revenue by Company in 2025 (\$ millions)

Figure 52. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Company in 2025

Figure 53. Global GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Geographic Region (2021-2026)

Figure 54. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Geographic Region in 2025

Figure 55. Americas GLP-1 Combination and Multi-agonist Drugs Sales 2021-2026 (K Units)

Figure 56. Americas GLP-1 Combination and Multi-agonist Drugs Revenue 2021-2026 (\$ millions)

Figure 57. APAC GLP-1 Combination and Multi-agonist Drugs Sales 2021-2026 (K Units)

Figure 58. APAC GLP-1 Combination and Multi-agonist Drugs Revenue 2021-2026 (\$ millions)

Figure 59. Europe GLP-1 Combination and Multi-agonist Drugs Sales 2021-2026 (K Units)

Figure 60. Europe GLP-1 Combination and Multi-agonist Drugs Revenue 2021-2026 (\$ millions)

Figure 61. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales 2021-2026 (K Units)

Figure 62. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Revenue 2021-2026 (\$ millions)

Figure 63. Americas GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Country in 2025

Figure 64. Americas GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Country (2021-2026)

Figure 65. Americas GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Type (2021-2026)

Figure 66. Americas GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Application (2021-2026)

Figure 67. United States GLP-1 Combination and Multi-agonist Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 68. Canada GLP-1 Combination and Multi-agonist Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 69. Mexico GLP-1 Combination and Multi-agonist Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 70. Brazil GLP-1 Combination and Multi-agonist Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 71. APAC GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Region in 2025

Figure 72. APAC GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Region (2021-2026)

Figure 73. APAC GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Type (2021-2026)

Figure 74. APAC GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Application (2021-2026)

Figure 75. China GLP-1 Combination and Multi-agonist Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 76. Japan GLP-1 Combination and Multi-agonist Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 77. South Korea GLP-1 Combination and Multi-agonist Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 78. Southeast Asia GLP-1 Combination and Multi-agonist Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 79. India GLP-1 Combination and Multi-agonist Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 80. Australia GLP-1 Combination and Multi-agonist Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 81. China Taiwan GLP-1 Combination and Multi-agonist Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 82. Europe GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Country in 2025

Figure 83. Europe GLP-1 Combination and Multi-agonist Drugs Revenue Market Share by Country (2021-2026)

Figure 84. Europe GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Type (2021-2026)

Figure 85. Europe GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Application (2021-2026)

Figure 86. Germany GLP-1 Combination and Multi-agonist Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 87. France GLP-1 Combination and Multi-agonist Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 88. UK GLP-1 Combination and Multi-agonist Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 89. Italy GLP-1 Combination and Multi-agonist Drugs Revenue Growth

2021-2026 (\$ millions)

Figure 90. Russia GLP-1 Combination and Multi-agonist Drugs Revenue Growth

2021-2026 (\$ millions)

Figure 91. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Country (2021-2026)

Figure 92. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Type (2021-2026)

Figure 93. Middle East & Africa GLP-1 Combination and Multi-agonist Drugs Sales Market Share by Application (2021-2026)

Figure 94. Egypt GLP-1 Combination and Multi-agonist Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 95. South Africa GLP-1 Combination and Multi-agonist Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 96. Israel GLP-1 Combination and Multi-agonist Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 97. Turkey GLP-1 Combination and Multi-agonist Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 98. GCC Countries GLP-1 Combination and Multi-agonist Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 99. Manufacturing Cost Structure Analysis of GLP-1 Combination and Multi-agonist Drugs in 2026

Figure 100. Manufacturing Process Analysis of GLP-1 Combination and Multi-agonist Drugs

Figure 101. Industry Chain Structure of GLP-1 Combination and Multi-agonist Drugs

Figure 102. Channels of Distribution

Figure 103. Global GLP-1 Combination and Multi-agonist Drugs Sales Market Forecast by Region (2027-2032)

Figure 104. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share Forecast by Region (2027-2032)

Figure 105. Global GLP-1 Combination and Multi-agonist Drugs Sales Market Share Forecast by Type (2027-2032)

Figure 106. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share Forecast by Type (2027-2032)

Figure 107. Global GLP-1 Combination and Multi-agonist Drugs Sales Market Share Forecast by Application (2027-2032)

Figure 108. Global GLP-1 Combination and Multi-agonist Drugs Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global GLP-1 Combination and Multi-agonist Drugs Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/GDBA2CECA37EEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GDBA2CECA37EEN.html>